Understanding the emotions of patients with inadequate response to antidepressant treatments: Results of an international online survey in patients with major depressive disorder by Mago, Rajnish et al.
RESEARCH ARTICLE Open Access
Understanding the emotions of patients
with inadequate response to
antidepressant treatments: results of an
international online survey in patients with
major depressive disorder
Rajnish Mago1*, Andrea Fagiolini2, Emmanuelle Weiller3 and Catherine Weiss4
Abstract
Background: Evidence suggests that nearly half of patients with major depressive disorder (MDD) do not achieve
an adequate response to antidepressant treatments (ADTs), which impacts patients’ functioning, quality of life (QoL),
and well-being. This patient survey aimed to better understand patient perspectives on the emotional impact of
experiencing an inadequate response to ADTs.
Methods: An online survey was conducted in 6 countries with respondents diagnosed with MDD and experiencing
an inadequate response to ADTs. The survey was designed to explore how patients felt about their medications
and health care provider (HCP). Those indicating they were ‘frustrated’ with their medications and/or HCP were
asked to provide reasons for their frustration and its impact on their relationship with their HCP and decisions
about their treatment.
Results: Overall, 2096 respondents with MDD and inadequate response to ADT completed the survey. The most
frequent emotion reported by patients regarding their medication was frustration (29.8% of respondents) followed by
hopeless (27.4%) and apprehensive/anxious/scared (27.4%). Regarding their HCP, patients reported feeling understood
(31.6%) and trusting/confident (28.8%) most often; however, 19.2% reported feelings of frustration. Main reasons for
frustration with medication were poor symptom control/lack of efficacy (59.3%) and tolerability issues (19.7%), and the
main reasons for frustration with their HCP were not feeling heard (22.4%), ineffective treatment (13.5%) and feeling
rushed/lack of quality visit (12.5%). The longer the current episode duration and the greater the disruption to daily
living, the more likely the respondents experienced feelings of frustration with medication. Feelings of frustration lead
to adherence issues, with 33.3 and 27.3% of respondents indicating their frustration with their medication and HCP,
respectively, made them want to quit their medication. Approximately one in six patients frustrated with either their
medication and/or HCP indicated their frustration had resulted in them not taking their medication regularly.
Frustration with their HCP also impacted patient’s confidence in HCPs abilities (34.7%), sharing less information with
their HCP (28.9%) as well as missing appointments (17.4%) and medications (14.5%).
Conclusions: Feelings of frustration are frequent in patients with inadequate response to ADT and this frustration may
impact treatment adherence and the patient-HCP relationship.
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Background
The treatment of major depressive disorder (MDD) has
progressed over the past several decades with greater
awareness and understanding of the disease, better diag-
nosis, and medications with improved tolerability. How-
ever, despite the treatment advances and availability of
multiple antidepressant classes/medications, approxi-
mately 50% of patients with MDD do not achieve an
adequate response to antidepressant treatment (ADT)
[1–3], as defined by a failure to achieve a response (50%
or greater reduction in the severity of the depression)
after treatment with an antidepressant at an adequate
dose and duration (i.e., at least 6–8 weeks) [4]. From the
patient perspective, people with MDD want their treat-
ment to help them return to their usual level of func-
tioning, return to their ‘usual self ’ and to regain
optimism and self-confidence [5].
Patients with inadequate response to ADT experience
significant impairments in social functioning and often
fail to regain a normal quality of life [6]. Work product-
ivity loss of those employed and higher unemployment,
along with higher emergency room utilization and
hospitalization are also associated with an inadequate re-
sponse to ADT [7]. Timely and effective treatment is im-
portant to prevent the long-term consequences of
prolonged inadequately-treated MDD [2].
While the personal burden of an inadequate response
can be significant and wide-ranging [8], little is known
on the emotional impact of inadequate response to
ADT. This survey set out to better understand the pa-
tient perspective on the emotional impact of experien-
cing an inadequate response to ADTs.
Specifically, the survey was designed to assess how fre-
quently different emotions were reported in people with
MDD experiencing an inadequate response to ADT, in-
cluding the frequency of feelings of frustration with
medication and their HCP. For those respondents who
reported feeling frustrated with their medication and/or
HCP, we sought to understand the reasons for their frus-
tration and the impact this frustration had on their
behavior.
Methods
Survey design and respondent criteria
This survey was conducted in the United States, Canada,
UK, Germany, France, and Spain between 15 March and
16 June, 2016. Respondents were recruited using con-
sumer panels where all panelists have provided consent
to participate in research. An online questionnaire was
used to screen respondents and collect quantitative data.
Access to the survey was secure, ensuring the anonymity
of respondents.
All respondents were eligible for the survey if they met
the following criteria: age 18 to 65 years, diagnosed with
depression by a healthcare professional; no comorbid
diagnoses of bipolar disorder, schizoaffective disorder, or
schizophrenia; experiencing symptoms of depression
most of the time over the past week; their depression
has a moderate to extreme impact on overall functioning
as measured by the Sheehan Disability Scale (SDS) [9];
has a psychiatrist or primary care physician (or, in the
US, a nurse practitioner or physician assistant) who is
primarily responsible for their treatment; currently on
an ADT for at least 6 weeks at an adequate dose (see
Appendix); they felt that their depression has not im-
proved or only a little since the onset of the current epi-
sode (as measured by the Patient Global Impression of
Improvement (PGI-I), and, finally, not working for a
biasing employer (advertising agency or marketing re-
search company or a company that manufactures, dis-
tributes or sells pharmaceuticals or health care
products). Finally, per pharmacovigilance compliance
regulations, all eligible respondents were required to
provide consent for disclosure of any adverse-events re-
ported within their responses.
Defining an “inadequate response” to ADT
Eligible survey participants all suffered from MDD with
a current episode having moderate to extreme impact on
overall functioning as measured by SDS, and to be on at
least one ADT at an adequate dose for at least 6 weeks.
Participants were considered as having an inadequate re-
sponse to their current ADT if they indicated that their
current symptoms had little to no improvement (based
on the 7-item PGI-C, ranging from very much worse to
very much improved).
Assessments
The survey was conducted as an online 20-min ques-
tionnaire. All data collected was self-reported by partici-
pants and included both close-ended and open
questions on the following topics: history of depression
(onset of first episode, number of lifetime episodes,
length of current episode), treatment history (hospitali-
zations, psychotherapy, treatment received for current
episode, reason for discontinuation); change on current
treatment (patients’ global impression of change, PGI-C),
current symptoms of depression, other current symp-
toms, impact of depression on functioning (SDS), treat-
ment goals, emotional feelings about their experience
with medication, healthcare providers and overall health-
care system, including feelings of frustration, intensity of
frustration and reasons for feeling frustrated. Here we
present the results pertaining to their feeling towards
medication and HCP.
Current symptoms of depression were assessed using a
modified version of the Patient Health Questionnaire
(PHQ-9) [10], excluding the question about suicidal
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ideation. The scale was the standard PHQ-9 where 0 =
Not at all, 1 = Several days, 2 =More than half of the
days and 3 = Nearly every day. Other (non-PHQ-9)
current symptoms were elicited from a check list of clin-
ical symptoms associated with depression (see list in
Fig. 1). The lists of emotional feelings regarding their
treatment and HCP, included in the survey were created
using direct patient input from qualitative interviews
conducted during the survey development (not shown).
Reasons for frustration were asked using a voluntary
open-end format and responses were manually coded.
Coded responses were validated by a second coder and
quality checked by a research analyst. A list of conse-
quences of frustration was also included in the survey
based on patient and physician input during pre-survey
qualitative interviews. To gauge the patient’s perception
on the overall level of impairment caused by their de-
pression, the survey included the additional PHQ item
10 “How difficult have these problems made it for you to
do your work, take care of things at home, or get along
with other people?”, where the scale included was 1 =
Not difficult at all, 2 = Somewhat difficult 3 = Very diffi-
cult and 4 = Extremely difficult.
Statistical analyses
Descriptive statistics included means and frequency of
responses (%). A driver analyses was conducted using
random forest analysis [11]. A random forest is a
method where many decision trees (500 in our analysis)
are constructed. The analysis selects a random sample of
cases as the training set for each tree, and at each poten-
tial branching of the tree, a random subset of variables is
evaluated as potential splits. The output of a random
forest analysis provides ratio-level data of the influence
that each characteristic has on the presence of
dependent variable. Higher scores mean that, on average,
the nodes created when the tree splits on this variable
are more homogenous than nodes created by splitting
on variables with lower scores – in other words they are
considered more important. Patient characteristics en-
tered as independent variables into the analysis included
time since first episode, past hospitalization, past psy-
chotherapy, number of episodes experienced, length of
current episode, number of ADT failures, current treat-
ment of monotherapy vs. combination therapy, change
on current treatment (PGI-C), level of impairment
(PHQ item 10) and disruption of daily living (SDS mean
score). The dependent variable was the presence of
moderate-to-severe frustration with their treatment. The
random forest analysis was performed using the “ran-
domForest” statistical package in R. Validity testing was
done using a logistic regression to determine the
explanatory power of the entered predictors.
Results
Respondent characteristics
A total of 18,083 adult (age 18–65) respondents diagnosed
with MDD by a health care professional with no comorbid
diagnoses of Bipolar Disorder, Schizoaffective or Schizo-
phrenia were identified through our screening process
using consumer panels (Fig. 1). Of the respondents with
MDD, 11,466 were currently suffering from symptoms of
depression and 93.5% of these (10,715) had at least a moder-
ate impact on functioning. Approximately 56.3% (n = 6037)
Fig. 1 Screening disposition for participation in online patient survey
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were being treated with an adequate dose of ADT for
at least six weeks under the supervision of a psych-
iatrist, primary care physician (or nurse practitioner
in the US). Of those adequately treated, 54% (3243)
were experiencing an inadequate response to ADT.
Finally, with drop-outs and quota caps at a country
level, a total of 2096 respondents with inadequate re-
sponse to ADT, completed the survey from six countries.
These included the US (597, 28.5%), Canada (301, 14.4%),
UK (300, 14.4%), Germany (299, 14.3%), France (299,
14.3%) and Spain (300, 14.4%).
The mean age of our survey respondents was 42.1 years
and 56.7% were female (Table 1). While more than half
of the respondents were working, 10% were on sick-
leave or disability due to depression. The mean duration
since onset of first episode was 10.5 years. Most respon-
dents (91.1%) had suffered recurrent episodes and 39.6%
had experienced over 10 episodes of depression. A third
(34%) had been hospitalized for depression and 79% had
received psychotherapy at some point.
Per the screening requirements, all respondents were
suffering from a current episode of depression. Just over
half (51.7%) had been experiencing their current episode
of depression for a year or less. Just over a third (38.1%)
were taking combination ADT (at least two classes), and
16.4% were taking an adjunctive antipsychotic (AP).
Despite ongoing AD treatment, nearly a quarter of pa-
tients (23.7%) indicated their depression had gotten
worse since the onset of their current episode, while an-
other 20.4% indicated no change, 48.7% indicated min-
imal improvement, and only 7.2% indicated moderate-
great improvement (PGI-C). The SDS mean score was
6.9, with mean domain scores of 7.5, 6.9 and 6.5 in
work/school, social life, and family life/home responsibil-
ities, respectively. Respondents’ rated their overall level
of impairment caused by depression as a mean of 2.8,
with 60.6% indicating ratings of very or extremely diffi-
cult (PHQ item 10). Analysis of individual PHQ-9 items
revealed that more than two-thirds of patients reported
feeling down, depressed or hopeless, or having little
interest or pleasure in doing things more than half the
days (33.3 and 30.6%, respectively) or nearly every day
(36.5 and 38.0%) (Additional file 1: Appendix). The most
frequently reported ongoing symptoms other than those
measured by PHQ-9, was lack of motivation (77.2%)
followed by anxiousness, irritability and excessive wor-
ries, (67.1%, 58.1 and 57.4%).
Respondent emotions regarding their medication
Respondents were asked to describe how they felt
about their prescription therapy and to select as many
feelings that were relevant to their situation. Frustra-
tion was the emotion selected most often (29.8%) by
respondents. Other emotions most often cited
included, hopeless (27.4%), apprehensive/ nervous/
anxious/scared (27.4%), resigned (26.9%), and dissatis-
fied (25.4%) (Fig. 2a). Of the respondents that indi-
cated they were frustrated with their treatment, 85.9%
rated their frustration as being moderate-to-severe
(Fig. 2b). In addition, these respondents reported high
Table 1 Demographic and clinical characteristics of
respondents (n = 2096)
CHARACTERISTIC N = 2096
Age; mean (years) 42.1
Gender; n (%) female 1188 (56.7)
Employment status; n (%)
Working full/part time 923 (44.0)
Working, but currently on a sick leave/disability
due to depression
219 (10.4)
Working, but currently on a sick leave/disability
for another reason
80 (3.8)
Unemployed 308 (14.7)
Retired 184 (8.8)
Student 80 (3.8)
Homemaker 170 (8.1)
Other 132 (6.3)
Time since first episode; mean (years) 10.5
Number of total episodes; n (%) of respondents
1 186 (8.9)
2–5 564 (26.9)
6–10 328 (15.6)
> 10 829 (39.6)
Don’t know 189 (9.0)
Recurrent episodes; n (%) of respondents 1721 (91.1)
Ever hospitalized for their depression; n (%) of respondents 713 (34.0)
Ever had psychotherapy; n (%) of respondents 1655 (79.0)
Duration of current episode; n (%) of respondents
0–6 months 766 (36.5)
7–12 months 319 (15.2)
2–5 years* 457 (21.8)
> 5 years* 554 (26.4)
Patients receiving two or more classes of ADT; n (%)
of respondents
799 (38.1)
Patients receiving adjunctive antipsychotic**; n (%)
of respondents
345 (16.4)
Number of ADT failures in current episode; n (%) of
respondents
1 361 (17.2)
2 722 (34.4)
3+ 1013 (48.3)
*Patients may have difficulties remembering symptom-free periods in between
2 episodes, leading to report of long lasting single episodes
**includes both atypical and typical antipsychotics
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levels of concomitant hopelessness (44.8% of those
frustrated), anxiousness (48.2%) and dissatisfaction
(44.8%) (Fig. 2c).
Respondent emotions regarding their HCP
Patients with an inadequate response to their ADT were
also asked how they felt about their HCP by selecting as
many feelings that were relevant to their situation. The
two most frequently chosen emotions were ‘feeling
understood’ (31.6%) and ‘trusting/confident’ (28.8%).
However, 19.2% of respondents reported frustration
(Fig. 3a). Of those indicating they were frustrated with
their HCP, 78% rated their frustration as being
moderate-to-severe (Fig. 3b). Finally, of the 38.0% of pa-
tients who reported being frustrated with medication
and/or their HCP, nearly a third reported frustration
Fig. 2 Respondent emotions regarding their medication (a) survey population (n = 2096), (b) severity of frustration when reported (n = 536), (c)
overlap of frustration with hopelessness, anxiousness and dissatisfaction
Fig. 3 Respondent emotions regarding their HCP (a) survey population (n = 2096), (b) severity of frustration when reported (n = 311)
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with both medication and their HCP (10.9% of all
respondents).
Reasons for feeling frustrated
Respondents who indicated they were moderately-to-
severely frustrated with either their treatment and/or their
HCP were asked why they were frustrated via an open-end
question format. Responses were then coded for select
themes and are shown in Fig. 4. The top reason for their
frustration with medication was lack of efficacy (59.3%)
followed by side-effect issues (19.7%). Other reasons in-
cluded having to take medication daily, failing to meet their
expectations, tapering effect, their relationship with their
physician and onset of action (Fig. 4). Frustration with their
HCP was driven by respondents feeling dismissed/HCP is
not listening to them (22.4%), current treatment not being
effective (13.5%) and lack of quality time spent with patient/
too rushed (12.5%) among other reasons shown in Fig. 4b.
Clinical characteristics associated with higher frequency
of frustration
Random forest analyses indicated that for both frustra-
tion with medication and frustration with HCP the three
largest drivers of frustration, of those entered in the
model, were length of current episode, time since first
episode and impact on function (SDS). Further, these
three were twice as important as PGI-C and number of
treatment failures (Fig. 5). The validity results however
yielded a very small effect (Nagelkerke R-square = 0.074
for medication and 0.087 for HCP).
Consequences/impact of feeling frustrated
Patients moderately-to-severely frustrated with their
treatment for depression were asked to identify how
their frustration impacts their behaviors and decisions
around their depression. The most frequently cited out-
comes of frustration include patients considering alter-
native medication options (35.5%), other therapeutic
approaches (33.8%) or simply quitting their medication
all together (33.3%) (Fig. 6a). Another 14.7% admit that
their frustration has resulted in them not taking their
medication on a regular basis (Fig. 6a).
Those frustrated with their HCP suggested the frustra-
tion made them want to find a new HCP (40.5%), ques-
tion the ability of their HCP (34.7%), share less
information with their HCP (28.9%) and quit their medi-
cation altogether (27.3%) (Fig. 6b).
Discussion
In line with the STAR*D study [3], our screening process
demonstrates that just over half (54%) of all patients be-
ing treated for an ongoing episode of depression experi-
ence an inadequate response, and that this is associated
with significant impairment in functioning (mean SDS
score of 6.9). Beyond the presence of unresolved symp-
toms and impaired functioning, the results of this pa-
tient survey further suggest that an inadequate response
to antidepressants may have other consequences that are
important to consider as a healthcare provider.
It has been suggested that protracted depressive illness
and treatment failure can lead to the erosion of critical
social support, along with increased interpersonal, voca-
tional and economic stress [12]. Studies have shown that
having an inadequate response increases the duration of
MDD and imposes a significant burden to society in
terms of healthcare costs and workplace productivity
losses [7]. This survey further supports the critical im-
portance of addressing inadequate response in a timely
and effective manner. Our results suggest that an
Fig. 4 Reasons for frustration with (a) medication (n = 536) and (b) HCP (n = 311)
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inadequate response to antidepressants is often associ-
ated with negative emotions towards medication and
HCP, including feelings of frustration, hopelessness and
dissatisfaction. Frustration was the most frequently cited
emotion regarding medication, with two in five patients
indicating their frustration. The primary reasons for
frustration with medication were directly related to the
unresolved symptoms and side-effects of ADTs. A major
finding of STAR*D was that likelihood of responding to
a third or fourth step treatment after failing the initial
two steps was < 20% [3]. Thus, the high levels of frustra-
tion with medication may reflect the fact that current
treatment approaches/medications have not been effect-
ive, and that there is still an unmet need for treatments
with an improved efficacy-tolerability profile.
In regards to HCPs, the most frequent emotions re-
ported by respondents included two positive feelings of
being understood, (31.6%) and confidence (28.8%), but
Fig. 5 Relative contribution of respondent characteristics on the presence of frustration with (a) medication (b) their HCP
Fig. 6 Consequences of frustration with (a) medication (n = 536) and (b) HCP (n = 311)
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the third most frequently cited emotion was frustration
(19.2%). Interesting insight was gleaned from respon-
dents when asked why they were frustrated with the
HCP. Along with citing lack of response/ineffective
treatment, patients identified dynamics of visit and rela-
tionship with HCPs. In fact, two of the top three reasons
cited included feeling like the HCP is not listening to
them/dismissing them and feeling like the visit is rushed
and does not allow for quality time/discussion. This
study also suggests that a patient who is frustrated with
their medication is 4 times more likely to be frustrated
with their HCP than those not frustrated with medica-
tion, underscoring the importance of addressing inad-
equate response to medication to assure good relations/
collaboration.
Evaluation of the drivers of frustration using a random
forest model showed that length of time since first epi-
sode, length of current episode and impact on function-
ing were the three highest predictors/drivers of
frustration, both with medication and with HCP. How-
ever, it is important to remember that our explanation
power, or lift in this case, is low suggesting there are
many things influencing feelings of frustration that are
not included in the model. For example, we observed
that patients in France were less likely to report frustra-
tion with medication or HCPs than patients in the US,
UK and Canada (data not shown). This may be due to
cultural differences or differences in the healthcare sys-
tem, but we were unable to explore this interesting ob-
servation within the limits of the survey design.
The results of this survey suggest that recognizing that
a patient is frustrated with his/her medication is import-
ant for a timely intervention to reduce the negative im-
pact of this frustration on adherence to treatment.
Overall, 15% and 17% of respondents who reported be-
ing moderately-to-severely frustrated with their medica-
tion or HCP, respectively, said they have already stopped
taking their medication on a regular basis. Another 33%
and 27% indicated that their frustration with their medi-
cation and HCP, respectively, makes them want to “quit
medication all together”. Moreover, nearly a third (29%)
of patients frustrated with their HCP admitted to sharing
less information, which may be critical to a treatment
approach with HCP. Thus, frustration may represent a
warning sign that a change in treatment is warranted.
Asking patients to talk about their feelings about treat-
ment and engaging patients on communicating their
frustration concretely may help strengthen the patient/
physician relationship and improve patient outcomes.
To the best of our knowledge, it is the first survey to
evaluate the impact of frustration in patients with MDD.
Strengths of this survey include its size and international
approach. While this allowed us to note some interesting
differences between countries, we did not explore the
influence of culture or differing healthcare systems on
the feelings of frustration. For example, we did not in-
clude type of healthcare (or type of healthcare provider)
in the random forest analysis. The survey was conducted
in Western countries, which limits its generalizability to
other regions of the world. Other limitations include
those inherent to patient self-report surveys, which are
based on the patient’s own understanding of their condi-
tion, and are not compared with objective clinical infor-
mation (e.g. about symptom severity, or response to
treatment). Indeed, since our intent was to examine the
patient perspective, we purposefully used subjective
scales (instead of more standard clinical scales) to define
an ‘inadequate response’ (PGI-C) and level of impair-
ment (PHQ-9 item 10). Patients were recruited from
existing consumer panels, and we do not know how this
may have biased the results. For example, it may be that
patients who are frustrated with their healthcare are
more likely to respond to health surveys. Conversely,
they could be less motivated to reply to the invitation.
In summary, this survey findings suggest that patients
with prolonged disease (total or current episode), mul-
tiple treatment failures and impact on daily living may
lead to feelings of frustration. In turn this frustration can
lead to destructive behaviors such as non-compliance,
mistrust of the HCP and patient’s withholding informa-
tion that may be relevant to treatment decisions.
Conclusions
Patients experiencing an inadequate response to treat-
ment not only have unresolved depressive symptoms but
also often have negative feelings about their failed treat-
ments. This survey suggests that inadequate response to
ADTs and continued trial-and-error of treatments can
result in frustration, dissatisfaction, and other negative
feelings towards medication and HCP. Since feelings of
frustration may lead to adherence issues it is important
that health care providers realize the emotional conse-
quences of inadequate treatment and strive to reduce
the levels of inadequate responses by exploring alterna-
tive treatment options.
Additional file
Additional file 1: Appendix. Table e1. Antidepressants taken by
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